EDAP Announces 23% First Quarter 2013 Revenue Growth
2013年4月11日 - 9:30PM
- First quarter total revenue of approximately EUR 5.9 million
(USD 7.8 million), up 23% year-over-year
- Ten lithotripsy devices sold in first quarter 2013
- Received FDA acceptance for PMA filing on March 26, 2013, for
Ablatherm®-HIFU for treatment of low risk, localized prostate
cancer
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, announced today preliminary unaudited revenues for the
first quarter ended March 31, 2013.
Preliminary total revenue for the first quarter 2013 is expected
to be approximately EUR 5.9 million (USD 7.8 million), a 23%
year-over-year increase. First quarter 2013 total revenue reflected
the sales of ten lithotripters and one Ablatherm-HIFU device.
Marc Oczachowski, EDAP's Chief Executive Officer, commented,
"Our first quarter 2013 revenue reflects the ongoing global demand
for our innovative range of lithotripsy offerings. We are
poised for continued growth as we expand our sales operations and
increase our market penetration."
EDAP plans to hold a conference call to discuss its first
quarter 2013 financial results on Thursday, May 16, 2013, at 8:30
am EDT.
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm® for high-intensity focused
ultrasound (HIFU) treatment of localized prostate cancer. HIFU
treatment is shown to be a minimally invasive and effective
treatment option with a low occurrence of side effects.
Ablatherm-HIFU is generally recommended for patients with localized
prostate cancer (stages T1-T2) who are not candidates for surgery
or who prefer an alternative option, or for patients who failed
radiotherapy treatment., Ablatherm-HIFU is approved and
commercialized in Europe as a treatment for prostate cancer and is
currently under regulatory review in the U.S. following submission
of the Pre-Market Approval Application in February 2013 after the
completion of a multi-center U.S. Phase II/III clinical trial
under an Investigational Device Exemption (IDE) granted by the FDA.
The Company also develops its HIFU technology for the potential
treatment of certain other types of tumors. EDAP TMS SA also
produces and commercializes medical equipment (the Sonolith® range)
for treatment of urinary tract stones using extra-corporeal
shockwave lithotripsy (ESWL). For more information on the Company,
please visit http://www.edap-tms.com, and
http://www.hifu-planet.com.
Forward-Looking Statements
In addition to historical information, this press release may
contain forward-looking statements that involve risks and
uncertainties. Such statements are based on management's current
expectations and are subject to a number of uncertainties,
including the uncertainties of the regulatory process, and risks
that could cause actual results to differ materially from those
described in these forward-looking statements. Factors that may
cause such a difference include, but are not limited to, those
described in the Company's filings with the Securities and Exchange
Commission and in particular, in the sections "Cautionary Statement
on Forward-Looking Information" and "Risk Factors" in the Company's
Annual Report on Form 20-F. Ablatherm-HIFU treatment is in clinical
trials, but not FDA-approved or marketed in the United States.
CONTACTS: Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA +33 4 72 15 31 72
bconfort@edap-tms.com
Investors:
Stephanie Carrington The Ruth Group
646-536-7017
scarrington@theruthgroup.com
EDAP TMS (NASDAQ:EDAP)
過去 株価チャート
から 9 2024 まで 10 2024
EDAP TMS (NASDAQ:EDAP)
過去 株価チャート
から 10 2023 まで 10 2024